Adaptive Biotechnologies vs Agenus
ADPT and AGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADPT and AGEN compare
Adaptive Biotechnologies is the larger company, worth 15 times as much as Agenus ($4.6B against $309M).
Agenus grew revenue faster over the last twelve months (25.4% versus 17.9% for Adaptive Biotechnologies).
Adaptive Biotechnologies scores higher on the StockData Score (12 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADPT | AGEN |
|---|---|---|
| Size and price | ||
| Market cap | $4.6B | $309M |
| Share price | $29.04 | $6.87 |
| Change, 1 year | 100% | 60.9% |
| Change, 5 years | 6.2% | −90.2% |
| Beta (5Y) | 1.79 | 2.03 |
| Employees | 624 | 81 |
| StockData Score | ||
| Total score | 12 (better) | 3 |
| Valuation score | 0 | 1 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 3 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.6× | 2.3× (better) |
| P/B | 26.3× | – |
| EV/EBITDA | – | 4.5× |
| FCF yield | −0.19% (better) | −33.6% |
| Fair value | $6.88 | – |
| Margin of safety | −322% | – |
| Growth | ||
| Revenue growth (TTM) | 17.9% | 25.4% (better) |
| Revenue growth, 5Y average | 23.0% (better) | 5.3% |
| Profitability | ||
| Gross margin | 74.2% | 100% (better) |
| Operating margin | −16.2% | 38.9% (better) |
| Net margin | −23.7% | – |
| FCF margin | −3.0% (better) | −77.5% |
| Return on equity | −37.1% | – |
| Return on invested capital | −9982% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | −1.05 |
| Interest coverage | −5.3× | 0.9× (better) |
| Current ratio | 3.97 (better) | 0.73 |
| Altman Z-score | 3.38 (better) | −10.71 |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.6% | 31.7% |
| Held by insiders | 22.7% | 6.6% |
| Insider net buying, 12 months | −$117M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.3% | 18.1% |
Go deeper
- ADPT stock overview
- ADPT income statement
- ADPT valuation and score
- AGEN stock overview
- AGEN income statement
- AGEN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.